尼古丁对帕金森病小鼠多巴胺能神经元的保护作用

目的：观察尼古丁对多巴胺能神经元的作用并探讨其作用机制。方法：采用1-甲基-4-苯基-1,2,3,6-四氢吡啶（1-methyl-4-phenyl—1,2,3,6-tetrahydmpyridine,MPTP）小鼠模型,通过行为学方法、免疫组织化学、电镜观察尼古丁预处理对帕金森病（parkinson’s disease,PD）小鼠的影响。结果：尼古丁预处理可以明显缩短PD小鼠的爬杆时间,提高悬挂的得分。免疫组化结果显示尼古丁显著减少多巴胺（doparnine,DA）能神经元变性（P〈0．01）和γ-氨基丁酸（γ-aminobutyric acid,GABA）能神经元的脱失（P〈0．05）,并可减轻尾核超微结构的损伤。结论：尼古丁可减轻MPTP小鼠多巴胺能神经元的损伤,对多巴胺能神经元有保护作用。     

腺苷受体拮抗剂对帕金森病小鼠神经递质的影响

运用神经毒剂ＭＰＴＰ（１－ｍｅｔｈｙ－４－ｐｈｅｎｙ－１,２,３,６－ｔｅｔｒａｈｙｄｒｏｐｙｒｉｄｉｎｅ）制作的ＩＣＲ小鼠帕金森病模型,通过荧光测定方法和免疫组织化学方法,测定ＭＰＴＰ及腺甘Ａ２ａ受体拮抗剂喹唑啉（Ｑｕｉｎａｚｏｌｉｎｅ,ＣＰ６６７１３）对单胺类神经递质去甲肾上腺素（ＮＡ）、多巴胺（ＤＡ）、５－羟色胺（５－ＨＴ）及其代谢产物５－羟吲哚乙酸（５－ＨＩＡＡ）和氨基酸类神经递质γ－氨基     

溶酶体抑制剂对小鼠行为学与黑质多巴胺神经元的影响

目的初步探讨溶酶体抑制剂对小鼠行为学及多巴胺神经元功能的影响。方法于小鼠右侧中脑黑质（SN）区,立体定向微量注入溶酶体抑制剂和蛋白酶体抑制剂。观察阿朴吗啡诱导的小鼠旋转行为改变以及行为学变化;检测黑质区酪氨酸羟化酶（TH）阳性细胞数。结果阿朴吗啡未能诱导出小鼠旋转行为。蛋白酶体抑制剂组为10～15圈。多巴胺损害程度与溶酶体的剂量相关。磷酸氯喹25μmol/L时多巴胺神经元几乎没有损害作用;50μmol/L时局部区域多巴胺神经元有轻微损害;100μmol/L时损害明显;200μmol/L时黑质区注射局部神经元损害最严重,黑质注射区未见有神经元存在。1～4周呈现出较为明显逐渐恢复的特点。结论溶酶体功能抑制与多巴胺神经元凋亡相关,不同剂量溶酶体抑制剂在不同时间对多巴胺神经功能的损害不同。     

帕金森病黑质多巴胺神经元易损伤性的内在因素

帕金森病（Parkinson’s disease,PD）主要症状是由中脑黑质致密部（substantia nigra compact,SNc）的多巴胺（dopamine,DA）神经元死亡引起。帕金森病发病过程中,路易小体病理（Lewy pathology,LP）和线粒体功能障碍最为突出,但SNc 多巴胺神经元为什么特别易遭受这两种病理损害尚不清楚。研究表明,与脑内其他神经元相比,SNc 多巴胺神经元具有特殊的解剖形态、生理和生化表型。SNc 多巴胺神经元具有高分支无髓鞘轴突和众多的突触终端,突触末梢物质和能量代谢的高要求需要大量的线粒体,巨大突触终端增加了突触蛋白质的表达、转运和降解的负担。SNc 多巴胺神经元具有独特的自主起搏电活动和缓慢钙振荡特性,Cav1-3钙通道活动及后续的级联反应增加了SNc 多巴胺神经元线粒体负担,增加了基础氧化应激、线粒体损伤和自噬,降低了处理错误折叠蛋白质的能力。SNc 多巴胺神经元特有的神经递质——多巴胺易被氧化成为反应性醌,具有潜在毒性,可破坏葡糖脑苷脂酶导致其活性降低,引起线粒体氧化应激和溶酶体功能障碍。总之,SNc 多巴胺神经元具有的这些内在因素综合起来,可能导致了其对线粒体功能障碍和路易小体病理损伤的易感性,并且SNc 多巴胺神经元所处的神经网络障碍也促使了帕金森病的进展。认识到这些特征会对研究帕金森病相关病理学机制和阻止疾病进展创造新的机会。     

帕金森病黑质多巴胺神经元易损伤性的内在因素

帕金森病（Parkinson’s disease,PD）主要症状是由中脑黑质致密部（substantia nigra compact,SNc）的多巴胺（dopamine,DA）神经元死亡引起。帕金森病发病过程中,路易小体病理（Lewy pathology,LP）和线粒体功能障碍最为突出,但SNc 多巴胺神经元为什么特别易遭受这两种病理损害尚不清楚。研究表明,与脑内其他神经元相比,SNc 多巴胺神经元具有特殊的解剖形态、生理和生化表型。SNc 多巴胺神经元具有高分支无髓鞘轴突和众多的突触终端,突触末梢物质和能量代谢的高要求需要大量的线粒体,巨大突触终端增加了突触蛋白质的表达、转运和降解的负担。SNc 多巴胺神经元具有独特的自主起搏电活动和缓慢钙振荡特性,Cav1-3钙通道活动及后续的级联反应增加了SNc 多巴胺神经元线粒体负担,增加了基础氧化应激、线粒体损伤和自噬,降低了处理错误折叠蛋白质的能力。SNc 多巴胺神经元特有的神经递质--多巴胺易被氧化成为反应性醌,具有潜在毒性,可破坏葡糖脑苷脂酶导致其活性降低,引起线粒体氧化应激和溶酶体功能障碍。总之,SNc 多巴胺神经元具有的这些内在因素综合起来,可能导致了其对线粒体功能障碍和路易小体病理损伤的易感性,并且SNc 多巴胺神经元所处的神经网络障碍也促使了帕金森病的进展。认识到这些特征会对研究帕金森病相关病理学机制和阻止疾病进展创造新的机会。     

多巴胺能神经元线粒体的氧化损伤与帕金森病

帕金森病(Parkinson’s disease,PD)的一个主要病理特征就是中脑黑质多巴胺能神经元的丧失,目前研究认为该病理变化与多种因素有关,包括蛋白质异常积聚、泛素蛋白酶体系统功能异常、神经炎症、线粒体损伤和氧化应激。在帕金森病人和动物模型中,中脑黑质有着明显的氧化改变。帕金森病的遗传和环境因素均会作用于线粒体,尤其对线粒体呼吸链复合体I有着抑制作用,造成线粒体损伤,产生活性氧(ROS)。活性氧的大量产生造成脂类、蛋白质和DNA的氧化,从而加剧多巴胺能神经元的线粒体和细胞损伤。多巴胺代谢过程中会产生活性氧,该自身代谢特点决定了多巴胺能神经元存在有较高的氧化应激,易受环境因素的影响。因而,线粒体的氧化损伤在帕金森病病理发生中起着重要作用。     

人参皂甙Rg1对去卵巢帕金森病模型大鼠黑质多巴胺能神经元的保护作用

目的：探讨人参皂甙Rg1对6-羟基多巴（6-OHDA）制备的去卵巢（OVX）帕金森病（PD）模型大鼠黑质（SN）多巴胺能神经元的保护作用及其可能机制。方法：应用6-OHDA制备的OVX PD模型大鼠,侧脑室给予Rg1或雌激素。免疫组织化学染色酪氨酸羟化酶（TH）阳性神经元和Bcl-2蛋白。Perls’铁染色检测SN铁含量。结果：①Rg1或雌激素可抑制阿朴吗啡诱导的PD大鼠旋转行为;②在损毁侧SN,Rg1或雌激素用药组TH阳性神经元数量较6-OHDA组显著增多;③6-OHDA组损毁侧SN内铁含量较健侧明显升高,应用Rg1或雌激素后,SN铁含量较模型组明显减少;④与6-OHDA模型组相比,Rg1及雌激素均可增加损毁侧大鼠SN内Bcl-2蛋白表达。结论：人参皂甙Rg1具有类雌激素样作用,对OVX PD模型大鼠黑质DA能神经元有明显的保护作用,其作用机制可能与降低铁负载和抗凋亡有关。     

雌激素对6-羟基多巴胺损伤黑质多巴胺能神经元的保护作用

本研究以P50听觉诱发电位(P50 auditory evoked potential, P50)和酪氨酸羟化酶(tyrosine hydroxylase, TH)阳性细胞计数作为黑质功能和形态学指标,动态追踪研究雌激素对6-羟基多巴胺(6-hydroxydopamine, 6-OHDA)损伤黑质多巴胺(dopamine, DA)能神经元的作用.将大鼠分为4组:(1)正常雌性大鼠对照组;(2)单纯帕金森氏病(Parkinson's disease, PD)模型组;(3)双侧去卵巢PD模型组;(4)去卵巢回补3d雌激素的PD模型组.在大鼠清醒和安静的生理状态下连续14d记录黑质的P50,并检测黑质TH 细胞数目的变化.结果显示:单纯PD模型大鼠黑质P50的T/C值较正常雌鼠降低40.60%(P<0.01),其损伤侧黑质TH 细胞数目减少64.74%(P<0.01);去卵巢PD模型大鼠黑质P50的T/C值较单纯PD模型大鼠进一步降低45.88%(P<0.01),同时其黑质TH 细胞数目值也进一步减少57.26%(P<0.01),表明急性缺乏生理水平性腺雌激素将增大6-OHDA损伤黑质DA能神经元的程度,同时使黑质的感觉门控(sensory gating, SG)功能明显受损;去卵巢后回补3d生理剂量雌激素,可明显改善大鼠黑质的SG功能,提高TH 细胞数量(与去卵巢PD模型大鼠比较,P<0.01),其黑质损伤程度与单纯PD模型大鼠相当.以上结果提示,生理水平的雌激素具有提高黑质DA能神经元对伤害性刺激耐受性的神经保护作用.缺乏性腺源性的雌激素时,及时给予生理剂量的雌激素可以减轻神经毒素6-OHDA对黑质DA能神经元结构和功能的损伤.     

MPTP慢性帕金森病小鼠纹状体差异蛋白质的研究

目的分离、鉴定MPTP诱导慢性帕金森病模型小鼠纹状体差异表达的蛋白质,对MPTP慢性PD动物模型的特异性蛋白质组进行初步探讨,为PD的发病机制提供一定的蛋白质组学依据。方法成功建立MPTP诱导慢性帕金森病小鼠模型,提取模型组和对照组小鼠脑纹状体蛋白质,分别以固相pH梯度等电聚焦为第一向,SDS-PAGE垂直电泳为第二向进行2-DE。图像分析软件PDQUEST8.0分析电泳图谱找出差异表达蛋白,运用MALDI-TOF MS质谱鉴定;其肽质量指纹图（PMF）经MS Fit检索。结果比较MPTP诱导慢性PD模型小鼠和正常对照小鼠纹状体二向电泳图,发现12个蛋白表达异常,最终鉴定出其中4个蛋白质：线粒体裂殖调节因子1（mitochondrial fission regulator 1）、类泛素样蛋白3前体（ubiquitin-like protein 3 precursor）表达下调;S100蛋白A10（proteinS100-A10）、Lin-7 homolog B为新出现点。结论初步鉴定出MPTP慢性PD模型小鼠纹状体部分差异表达蛋白,所发现4个表达异常的蛋白质与帕金森病线粒体的损伤和兴奋性神经毒性密切相关,与PD的发病机制相符,为深入研究帕金森病病理机制奠定了基础。     

DJ-1保护大鼠中脑黑质多巴胺能神经元抵抗鱼藤酮损伤的研究

目的:探讨过表达DJ-1蛋白能否保护大鼠中脑黑质多巴胺能神经元抵抗鱼藤酮所致的急性损伤.方法:构建表达DJ-1基因的腺相关病毒载体(rAAV-DJ-1)并转染HEK-293细胞,进行腺相关假病毒颗粒包装,所得假病毒颗粒注射到大鼠脑内感染黑质神经细胞;4周后,注射鱼藤酮于大鼠黑质相同脑区;通过免疫组织化学和免疫印迹试验鉴定TH蛋白表达情况,采用动物行为轨迹分析软件计算大鼠30 min内运动距离以及强迫游泳试验鉴定大鼠精神症状.结果:与对照组相比,过表达D J-1组大鼠运动损伤症状较轻,精神症状改善明显;损伤侧黑质TH阳性神经元数目和TH蛋白表达水平显著高于对照组.结论:过表达DJ-1蛋白能保护大鼠黑质多巴胺能神经元抵抗鱼藤酮所致的急性损伤,延缓多巴胺能神经元的退行性变,提示DJ-1可能对帕金森病的治疗有较好的应用前景.     

Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP

Mutations in alpha-synuclein cause a form of familial Parkinson's disease (PD), and wild-type alpha-synuclein is a major component of the intraneuronal inclusions called Lewy bodies, a pathological hallmark of PD. These observations suggest a pathogenic role for alpha-synuclein in PD. Thus far, however, little is known about the importance of alpha-synuclein in the nigral dopaminergic pathway in either normal or pathological situations. Herein, we studied this question by assessing the expression of synuclein-1, the rodent homologue of human alpha-synuclein, in both normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice. In normal mice, detectable levels of synuclein mRNA and protein were seen in all brain regions studied and especially in ventral midbrain. In the latter, there was a dense synuclein-positive nerve fiber network, which predominated over the substantia nigra, and only few scattered synuclein-positive neurons. After a regimen of MPTP that kills dopaminergic neurons by apoptosis, synuclein mRNA and protein levels were increased significantly in midbrain extracts; the time course of these changes paralleled that of MPTP-induced dopaminergic neurodegeneration. In these MPTP-injected mice, there was also a dramatic increase in the number of synuclein-immunoreactive neurons exclusively in the substantia nigra pars compacta; all synuclein-positive neurons were tyrosine hydroxylase-positive, but none coexpressed apoptotic features. These data indicate that synuclein is highly expressed in the nigrostriatal pathway of normal mice and that it is up-regulated following MPTP-induced injury. In light of the synuclein alterations, it can be suggested that, by targeting this protein, one may modulate MPTP neurotoxicity and, consequently, open new therapeutic avenues for PD.     

Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice

Environmental and genetic factors that contribute to the pathogenesis of Parkinson's disease are discussed. Mutations in the alpha-synuclein (alphaSYN ) gene are associated with rare cases of autosomal-dominant Parkinson's disease. We have analysed the dopaminergic system in transgenic mouse lines that expressed mutant [A30P]alphaSYN under the control of a neurone-specific Thy-1 or a tyrosine hydroxylase (TH) promoter. The latter mice showed somal and neuritic accumulation of transgenic [A30P]alphaSYN in TH-positive neurones in the substantia nigra. However, there was no difference in the number of TH-positive neurones in the substantia nigra and the concentrations of catecholamines in the striatum between these transgenic mice and non-transgenic littermates. To investigate whether forced expression of [A30P]alphaSYN increased the sensitivity to putative environmental factors we subjected transgenic mice to a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) regimen. The MPTP-induced decrease in the number of TH-positive neurones in the substantia nigra and the concentrations of catecholamines in the striatum did not differ in any of the [A30P]alphaSYN transgenic mouse lines compared with wild-type controls. These results suggest that mutations and forced expression of alphaSYN are not likely to increase the susceptibility to environmental toxins in vivo.     

The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities

1. In this article we review the studies of memory disabilities in a rat model o Parkinson's disease (PD).2. Intranigral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to rats causes a partial lesion in the substantia nigra, compact part (SNc) and a specific loss of dopamine and its metabolites in the striatum of rats.3. These animals present learning and memory deficits but no sensorimotor impairments, thus modeling the early phase of PD when cognitive impairments are observed but the motor symptoms of the disease are barely present.4. The cognitive deficits observed in these animals affect memory tasks proposed to model habit learning (the cued version of the water maze task and the two-way active avoidance task) and working memory (a working memory version of the water maze), but spare long-term spatial memory (the spatial reference version of the Morris water maze).5. The treatment of these animals with levodopa in a dose that restores the striatal level of dopamine does not reverse these memory impairments, probably because this treatment promotes a high level of dopamine in extrastriatal brain regions, such as the prefrontal cortex and the hippocampus.6. On the other hand, the adenosine receptor antagonist, caffeine, partly reverse the memory impairment effect of SNc lesion in these rats. This effect may be due to caffeine action on nigrostriatal neurons, since it induces dopamine release and modulates the interaction between adenosine and dopamine receptor activity.7. These results suggest that the MPTP SNc-lesioned rats are a good model to study memory disabilities related to PD and that caffeine and other selective A(2A) adenosine receptor antagonists are promising drugs to treat this symptoms in PD patients.     

Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice

Acute administration of repeated doses of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) dramatically reduces striatal dopamine (DA) content, tyrosine hydroxylase (TH), and DA transporter-immunoreactivity in mice. In this study, we show for the first time the spatiotemporal pattern of dopaminergic damage and related molecular events produced by MDMA administration in mice. Our results include the novel finding that MDMA produces a significant decrease in the number of TH-immunoreactive neurons in the substantia nigra (SN). This decrease appears 1 day after injection, remains stable for at least 30 days, and is accompanied by a dose-dependent long-lasting decrease in TH- and DA transporter-immunoreactivity in the striatum, which peaked 1 day after treatment and persisted for at least 30 days, however, some recovery was evident from day 3 onwards, evidencing sprouting of TH fibers. No change is observed in the NAc indicating that MDMA causes selective destruction of DA-containing neurons in the nigrostriatal pathway, sparing the mesolimbic pathway. The expression of Mac-1 increased 1 day after MDMA treatment and glial fibrillary acidic protein increased 3 days post-treatment in the striatum and SN but not in the NAc, in strict anatomical correlation with dopaminergic damage. These data provide the first evidence that MDMA causes persistent loss of dopaminergic cell bodies in the SN.     

大鼠黑质多巴胺能神经元的二型性

成年哺乳动物的某些脑区存在性别差异,即二型性,但中脑黑质是否存在性分化目前不清楚。本文旨在探讨成年大鼠中脑黑质是否存在二型性。将60只成年大鼠分成5组：（1）正常雌鼠对照组：（2）正常雄鼠对照组：（3）去卵巢组;（4）去睾丸组;（5）去卵巢后回补雌激素组,该组大鼠在去卵巢后的第7天开始连续3d给予生理剂量的雌激素回补。所有大鼠在右侧黑质埋置记录电极,在清醒和安静的生理状态下连续14d记录黑质的P50听觉诱发电位（P50）,之后作黑质酪氨酸羟化酶（tyrosine hydroxylase,TH）免疫组织化学染色,检查TH阳性（TH^＋）细胞数量和形态变化。结果表明,正常成年雄鼠黑质的TH^＋细胞数量较雌鼠少22．47％（P〈0．05）,P50的T／C值也低34．72％（P〈0．01）,提示正常成年大鼠黑质在结构和功能上存在二型性。与正常雄鼠相比,去睾丸大鼠黑质的TH^＋细胞数量、形态和P50的T／C值无显著性变化（P〉0．05）。与正常雌鼠相比,去卵巢大鼠黑质TH^＋细胞数量减少28．09％（P〈0．01）,P50的T／C值降低30．85％（P〈0．01）。在大鼠去卵巢后的短时间内给予3d生理剂量的雌激素,15-20d后可观察到其黑质TH^＋细胞数量、形态和P50的T／C值基本恢复到去卵巢前水平。结果提示,大鼠中脑黑质的多巴胺能神经元在数量、结构和功能活动上存在性别差异：内源性雌激素在维持黑质多巴胺系统完整性及调节其功能活动中起重要作用。     

Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study

Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa ( l -dopa) and dopamine agonists have been most commonly used for symptomatic treatment. However, there are discrepancies between clinical and experimental data with respect to the neuroprotective effects of these drugs on dopaminergic neurons. In this study, to determine whether l -dopa is toxic or dopamine agonist is neuroprotective to dopaminergic neurons, we evaluated the neuroprotective properties of l -dopa and the pramipexol (PPX), one of dopamine agonists, with a focus on the regulatory effects of the anti-oxidant properties and cell survival or apoptotic signal pathways in the same experimental design, using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated PD animals. The glutathione level in MPTP-treated mice was significantly increased by PPX administration but not by L-dopa treatment. The expression of phosphorylated extracellular signal regulated kinase in MPTP-treated mice was significantly increased only with l -dopa treatment. Treatment with either l -dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice. Immunohistochemical analysis showed that both l -dopa and PPX increased significantly survival of dopaminergic neurons in MPTP-treated mice. Our study demonstrated that both l -dopa and PPX had comparable neuroprotective properties for dopaminergic neurons in MPTP-treated PD animal models, through modulation of cell survival and apoptotic pathways.     

Mitochondrial factors involved in Parkinson's disease by MPTP toxicity inMacaca fascicularis and drug effect

The maximal rates (V_max) of some mitochondrial enzyme activities related to energy transduction (citrate synthase, succinate dehydrogenase, malate dehydrogenase, NADH-cytochrome c reductase, cytochrome oxidase) and amino acid metabolism (glutamate dehydrogenase, glutamate-pyruvate-and glutamate-oxaloacetate-transaminases) were evaluated in non-synaptic (free) and intrasynaptic light and heavy mitochondria fromhippocampus ofMacaca fascicularis (Cynomolgus monkey). The different mitochondrial populations were isolated from thehippocampus of monkeys treated p.o. with dihydroergocriptine at a dose of 12 mg/kg/day before and during the induction of a Parkinson's-like syndrome by MPTP administration (i.v., 0.3 mg/kg/day for 5 days). The MPTP administration modified the activity of some enzymes related to the metabolism of glutamate and the activity of succinate dehydrogenase on selected types of mitochondria. Pharmacological treatment by dihydroergocriptine promoted return to the steady-state levels of most enzymes, demonstrating a protective effect on these biochemical parameters.     

TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP

Disturbances in Ca²⁺ homeostasis have been implicated in a variety of neuropathological conditions including Parkinson's disease (PD). However, the importance of store-operated Ca²⁺ entry (SOCE) channels in PD remains to be investigated. In the present study, we have scrutinized the significance of TRPC1 in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdro-pyridine (MPTP)-induced PD using C57BL/6 animal model and PC12 cell culture model. Both sub-acute and sub-chronic treatments of MPTP significantly reduced TRPC1, and tyrosine hydroxylase levels, but not TRPC3, along with increased neuronal death. Furthermore, MPTP induces mitochondrial dysfunction, which was associated with reduced mitochondrial membrane potential, decreased level of Bcl₂, Bcl-xl, and an altered Bcl-xl/Bax ratio thereby initiating apoptosis. Importantly, TRPC1 overexpression in PC12 cells showed significant protection against MPP⁺ induced neuronal apoptosis, which was attributed to the restoration of cytosolic Ca²⁺ and preventing loss of mitochondrial membrane potential. Silencing of TRPC1 or addition of TRPC1 channel blockers decreased mitochondrial membrane potential, whereas activation of TRPC1 restored mitochondrial membrane potential in cells overexpressing TRPC1. TRPC1 overexpression also inhibited Bax translocation to the mitochondria and thereby prevented cytochrome c release and mitochondrial-mediated apoptosis. Overall, these results provide compelling evidence for the role of TRPC1 in either onset/progression of PD and restoration of TRPC1 levels could limit neuronal degeneration in MPTP mediated PD.     

Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson’s disease

Adenosine A_2A receptors antagonists produce neuroprotective effects in animal models of Parkinson’s disease (PD). As neuroinflammation is involved in PD pathogenesis, both neuronal and glial A_2A receptors might participate to neuroprotection. We employed complementary pharmacologic and genetic approaches to A_2A receptor inactivation, in a multiple MPTP mouse model of PD, to investigate the cellular basis of neuroprotection by A_2A antagonism. MPTP·HCl (20 mg/kg daily for 4 days) was administered in mice treated with the A_2A antagonist SCH58261, or in conditional knockout mice lacking A_2A receptors on forebrain neurons (fbnA_2AKO mice). MPTP‐induced partial loss of dopamine neurons in substantia nigra pars compacta (SNc) and striatum (Str), associated with increased astroglial and microglial immunoreactivity in these areas. Astroglia was similarly activated 1, 3, and 7 days after MPTP administration, whereas maximal microglial reactivity was detected on day 1, returning to baseline 7 days after MPTP administration. SCH58261 attenuated dopamine cell loss and gliosis in SNc and Str. Selective depletion of A_2A receptors in fbnA_2AKO mice completely prevented MPTP‐induced dopamine neuron degeneration and gliosis in SNc, and partially counteracted gliosis in Str. Results provide evidence of a primary role played by neuronal A_2A receptors in neuroprotective effects of A_2A antagonists in a multiple MPTP injections model of PD. With the symptomatic antiparkinsonian potential of several A_2A receptor antagonists being pursued in clinical trials, this study adds to the rationale for broader clinical benefit and use of these drugs early in the treatment of PD.